European commission approves expanded label for kaftrio® in combination with ivacaftor for people with cystic fibrosis

London--(business wire)--vertex pharmaceuticals (nasdaq: vrtx) today announced that the european commission has granted regulatory approval for a label expansion of kaftrio® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of people with cystic fibrosis (cf). with this approval, the indication has been expanded to include all patients ages 2 years and older who have at least one non-class i mutation in the cystic fibrosis conductance regulator (cftr).
VRTX Ratings Summary
VRTX Quant Ranking